Kitagawa et al.8reported that ICI retreatment based on switching administration of anti‐PD‐1 and anti‐PD‐L1 antibodies in NSCLC patients has a median PFS of 4.0 months. The gene discussed is CD274; the disease is non-small cell lung carcinoma.